Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,654
  • Shares Outstanding, K 13,450
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,590 K
  • 60-Month Beta 0.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +117,629.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +13.46%
on 07/15/20
2.1700 -32.03%
on 07/30/20
+0.0950 (+6.88%)
since 07/02/20
3-Month
1.2800 +15.23%
on 05/06/20
3.1600 -53.32%
on 06/08/20
+0.1004 (+7.30%)
since 05/01/20
52-Week
1.0000 +47.50%
on 03/18/20
3.1700 -53.47%
on 12/16/19
-0.3197 (-17.81%)
since 08/02/19

Most Recent Stories

More News
Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call

Developments to be Shared by Dr. Jack Reich, Director, Dr. Bankole A. Johnson, Chief Medical Officer, William B. Stilley, III, Chief Executive Officer, and Joseph A. M. Truluck, Chief Financial Officer...

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder

EMA Agreement paves the way for a marketing authorization in Europe after Phase 3

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia

CHARLOTTESVILLE, VA / ACCESSWIRE / July 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL:ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland

Polish clinical sites initiated less than two weeks after regulatory approval

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia

ONWARD™ trial progresses with the opening of sites in Latvia

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering

CHARLOTTESVILLE, VA / ACCESSWIRE / June 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for...

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland

Achievement of Poland Approval an Important Milestone in Advancement of Trial

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals Receives Order for 1,000 COVID-19 Antibody Test Kits

Initial Customer Order Scheduled for Immediate Delivery

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market

CHARLOTTESVILLE, VA / ACCESSWIRE / June 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for addiction...

ADIL : 1.4850 (-7.76%)
Adial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests

Antibody Testing Available for Landmark ONWARD(TM) Pivotal Phase 3 Trial Participants

ADIL : 1.4850 (-7.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade ADIL with:

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

2nd Resistance Point 1.9500
1st Resistance Point 1.7800
Last Price 1.4850
1st Support Level 1.5100
2nd Support Level 1.4100

See More

52-Week High 3.1700
Fibonacci 61.8% 2.3411
Fibonacci 50% 2.0850
Fibonacci 38.2% 1.8289
Last Price 1.4850
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar